Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. 1995

J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
University of Amsterdam, Faculty of Medicine, Department of Neurology, The Netherlands.

Sixty patients with idiopathic cervical dystonia were treated a total of 240 times with botulinum toxin type A (BTA). Selected muscles were injected with BTA under electromyographic (EMG) guidance. The clinical effect was measured on the Tsui scale and a 10-point anchored visual analogue scale. A dosage of 150-300 mouse units was used in 77% of the treatments (mean 204 mouse units). Based on the Tsui scale, 45% of 240 treatments were still effective at the moment of reinjection (median improvement 2 points). Based on the 10-point anchored visual analogue scale, 73% of treatments were successful (median improvement 3 points). Forty-eight patients (80%) responded favourably to the treatment. Side-effects were mild and transient. Dysphagia occurred in 9% of treatments. Antibody production was investigated in 41 patients and was negative in all. A striking difference from previous reports is the lower dosage used in this study. The clinical response, however, was similar to that of other studies. We conclude that a dosage of 200-400 mouse units BTA (Dysport) may also be effective in the treatment of cervical dystonia, but with fewer side effects. EMG guidance and application of BTA into deep cervical muscles may further improve the clinical effect.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009333 Neck The part of a human or animal body connecting the HEAD to the rest of the body. Necks
D001905 Botulinum Toxins Toxic proteins produced from the species CLOSTRIDIUM BOTULINUM. The toxins are synthesized as a single peptide chain which is processed into a mature protein consisting of a heavy chain and light chain joined via a disulfide bond. The botulinum toxin light chain is a zinc-dependent protease which is released from the heavy chain upon ENDOCYTOSIS into PRESYNAPTIC NERVE ENDINGS. Once inside the cell the botulinum toxin light chain cleaves specific SNARE proteins which are essential for secretion of ACETYLCHOLINE by SYNAPTIC VESICLES. This inhibition of acetylcholine release results in muscular PARALYSIS. Botulin,Botulinum Neurotoxin,Botulinum Neurotoxins,Clostridium botulinum Toxins,Botulinum Toxin,Neurotoxin, Botulinum,Neurotoxins, Botulinum,Toxin, Botulinum,Toxins, Botulinum,Toxins, Clostridium botulinum
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004421 Dystonia An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77) Muscle Dystonia,Dystonia, Diurnal,Dystonia, Limb,Dystonia, Paroxysmal,Diurnal Dystonia,Dystonia, Muscle,Limb Dystonia,Paroxysmal Dystonia
D004576 Electromyography Recording of the changes in electric potential of muscle by means of surface or needle electrodes. Electromyogram,Surface Electromyography,Electromyograms,Electromyographies,Electromyographies, Surface,Electromyography, Surface,Surface Electromyographies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
June 1991, Clinical neuropharmacology,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
January 2016, SpringerPlus,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
November 1995, Movement disorders : official journal of the Movement Disorder Society,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
November 1998, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
November 2000, European journal of neurology,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
January 2006, Revista de neurologia,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
March 2019, American journal of physical medicine & rehabilitation,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
January 1988, Advances in neurology,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
January 1998, Neurologia i neurochirurgia polska,
J W Brans, and I P de Boer, and M Aramideh, and B W Ongerboer de Visser, and J D Speelman
July 2001, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!